Abstract
The smallpox vaccine based on the vaccinia virus was successfully used to eradicate smallpox, but although very effective, it was a very reactogenic vaccine and responsible for the deaths of one to two people per million vaccinated. Modified Vaccinia virus Ankara (MVA) is an attenuated derivative, also used in the smallpox eradication campaign and now being developed as a recombinant viral vector to produce vaccines against infectious diseases and cancer. MVA can encode one or more foreign antigens and thus can function as a multivalent vaccine. The vector can be used at biosafety level 1, has intrinsic adjuvant properties, and induces humoral and cellular immune responses. Many clinical trials of these new vaccines have been conducted, and the safety of MVA is now well documented. Immunogenicity is influenced by the dose and vaccination regimen, and information on the efficacy of MVA-vectored vaccines is now beginning to accumulate. In this chapter, we provide protocols for generation, isolation, amplification, and purification of recombinant MVA for preclinical and clinical evaluation.
*These authors contributed equally in this work.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gilbert SC (2013) Clinical development of modified vaccinia virus Ankara vaccines. Vaccine 31:4241–4246
Overton ET, Stapleton J, Frank I, Hassler S, Goepfert PA, Barker D, Wagner E, vonKrempelhuber A, Virgin G, Meyer TP, Muller J, Badeker N, Grunert R, Young P, Rosch S, Maclennan J, Arndtz-Wiedemann N, Chaplin P (2015) Safety and immunogenicity of modified vaccinia Ankara-Bavarian nordic smallpox vaccine in vaccinia-naive and experienced human immunodeficiency virus-infected individuals: an open-label, controlled clinical phase II Trial. Open Forum Infect Dis 2 ofv040
Baur K, Brinkmann KI, Schweneker M, Patzold J, Meisinger-Henschel C, Hermann J, Steigerwald R, Chaplin P, Suter M, Hausmann J (2010) Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses. J Virol 84:8743–84852
Orubu T, Alharbi NK, Lambe T, Gilbert SC, Cottingham MG (2012) Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA. PLoS One 7:e40167
Chakrabarti S, Sisler JR, Moss B (1997) Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 23:1094–1097
Cochran MA, Puckett C, Moss B (1985) In vitro mutagenesis of the promoter region for a vaccinia virus gene: evidence for tandem early and late regulatory signals. J Virol 54:30–37
Wyatt LS, Shors ST, Murphy BR, Moss B (1996) Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 14:1451–1458
Yao XD, Evans DH (2001) Effects of DNA structure and homology length on vaccinia virus recombination. J Virol 75:6923–6932
Moss B (1991) Vaccinia virus: a tool for research and vaccine development. Science 252:1662–1667
Hernandez R, Brown DT (2010) Growth and maintenance of chick embryo fibroblasts (CEF). Curr Protoc Microbiol Appendix 4: pp 4I
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Pavot, V., Sebastian, S., Turner, A.V., Matthews, J., Gilbert, S.C. (2017). Generation and Production of Modified Vaccinia Virus Ankara (MVA) as a Vaccine Vector. In: Ferran, M., Skuse, G. (eds) Recombinant Virus Vaccines. Methods in Molecular Biology, vol 1581. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6869-5_6
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6869-5_6
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6867-1
Online ISBN: 978-1-4939-6869-5
eBook Packages: Springer Protocols